创伤性脑损伤患者早期使用塞来昔布
该回顾性队列研究利用TriNetX全球健康研究网络的电子病历数据,纳入创伤性脑损伤(TBI)患者,比较使用与未使用塞来昔布、布洛芬、地塞米松患者的结局,主要终点为1年生存。倾向评分匹配后,塞来昔布组与无塞来昔布组各1443例,塞来昔布组1年内死亡92例(6.4%),无塞来昔布组145例(10.0%)(OR 0.61;95%CI 0.46-0.80;p=0.0003);1年生存率塞来昔布组96.1% vs 无塞来昔布组93.1%(p<0.0001)。塞来昔布还与较低的胃造瘘管依赖(p=0.017)、癫痫发作(p=0.027)和心肌梗死(p=0.021)相关。布洛芬也与更高的1年生存概率和更低的TBI后并发症相关;地塞米松与更广泛的并发症相关,但与更高的1年生存概率相关。作者认为该人群水平研究为COX抑制剂改善TBI结局提供了提示性支持,应在前瞻性临床研究中进一步探讨。
要点
- TBI后5天内早期使用塞来昔布与1年生存率更高相关:塞来昔布组96.1% vs 无塞来昔布组93.1%(p<0.0001)。
- 倾向评分匹配后塞来昔布组1年内死亡6.4%(92/1443),无塞来昔布组10.0%(145/1443),OR 0.61(95%CI 0.46-0.80;p=0.0003)。
- 塞来昔布与较低的胃造瘘管依赖(p=0.017)、癫痫发作(p=0.027)和心肌梗死(p=0.021)相关。
- 布洛芬也与更高的1年生存概率和更低的TBI后并发症相关;地塞米松与更广泛的并发症相关,但与更高的1年生存概率相关。
- 作者认为该回顾性人群研究为COX抑制改善TBI结局提供提示性支持,需前瞻性临床研究验证。
适用人群与场景
- 创伤性脑损伤(TBI)患者,数据来自TriNetX全球健康研究网络的电子病历,通过ICD-10和药房编码识别使用与未使用塞来昔布、布洛芬、地塞米松的患者。
- 分析基于倾向评分匹配及未匹配队列,匹配因素包括人口学特征、合并症和神经损伤。
处置流程与药物剂量
- 早期使用定义为TBI后5天内使用塞来昔布、布洛芬或地塞米松;原文未给出具体剂量、给药途径和疗程。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用TriNetX全球健康研究网络数据。
- 倾向评分匹配后塞来昔布组和无塞来昔布组各1443例;塞来昔布组1年内死亡92例(6.4%),无塞来昔布组145例(10.0%),OR 0.61(95%CI 0.46-0.80;p=0.0003)。
- 1年生存率塞来昔布组96.1% vs 无塞来昔布组93.1%(p<0.0001)。
- 1年时塞来昔布与较低的胃造瘘管依赖(p=0.017)、癫痫发作(p=0.027)和心肌梗死(p=0.021)相关。
- 布洛芬也与更高的1年生存概率和更低的TBI后并发症相关;地塞米松与更广泛的并发症相关,但与更高的1年生存概率相关。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,TBI后5天内早期使用塞来昔布和布洛芬与更高的1年生存概率和更少的并发症相关;该人群水平研究为COX抑制改善TBI结局提供提示性支持,应在前瞻性临床研究中进一步探讨。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) can cause rapid brain inflammation. There is debate over the safety and efficacy of anti-inflammatory agents in its treatment. With a particular focus on cyclooxygenase 2 (COX2) selective inhibition, we sought to determine the impact of celecoxib versus no celecoxib treatment on outcomes in patients with TBI and compare these with outcomes associated with nonselective COX inhibition (ibuprofen) and corticosteroid (dexamethasone) treatment.
METHODS: This retrospective cohort study used TriNetX, a large publicly available global health research network, to gather clinical data extracted from the electronic medical records. Using International Classification of Diseases, Tenth Revision and pharmacy codes, we identified patients with TBI who were and were not treated with celecoxib, ibuprofen, and dexamethasone. Analysis was performed on propensity-matched and unmatched cohorts, which were matched on demographics, comorbidities, and neurological injuries. Our primary end point was 1-year survival. Secondary end points were ventilator and tracheostomy dependence, gastrostomy tube placement, seizures, and craniotomy.
RESULTS: After propensity score matching, a total of 1443 patients were identified in both the celecoxib and no celecoxib cohorts. Ninety-two (6.4%) patients in the celecoxib cohort died within 1 year following TBI versus 145 (10.0%) in the no celecoxib cohort (odds ratio 0.61; 95% confidence interval 0.46-0.80; p = 0.0003). The 1-year survival rate was 96.1% in the celecoxib cohort versus 93.1% in the no celecoxib cohort (p < 0.0001). At the end of the 1-year period, celecoxib was associated with significantly lower gastrostomy tube dependence (p = 0.017), seizure activity (p = 0.027), and myocardial infarction (p = 0.021) compared with the control cohort. Ibuprofen was also associated with higher 1-year survival probability and lower rates of post-TBI complications. Dexamethasone was broadly associated with higher morbidity but was associated with higher 1-year survival probability compared with the no dexamethasone cohort.
CONCLUSIONS: Early celecoxib and ibuprofen use within 5 days post TBI was associated with higher 1-year survival probabilities and fewer complications. With emerging yet controversial preclinical evidence to suggest that COX inhibition improves TBI outcomes, this population-level study offers suggestive support for these drugs' clinical benefit, which should be pursued in prospective clinical studies.
参考来源
- Bhanja D, Hallan DR, Staub J, et al. Early Celecoxib use in Patients with Traumatic Brain Injury. Neurocrit Care. 2023. PMID: 37704936. doi:10.1007/s12028-023-01827-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。